Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Dobutamine in Septic Cardiomyopathy with Tissue Hypoperfusion
2024-517839-50-00Phase 4Completed
- Sponsor
- CHU de Limoges
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in septic shock, sepsis and septic cardiomyopathy (SCM) comparing Dobutamine with Placebo (2 arms). Primary endpoint: Change in modified SOFA score (excluding neurologic component). Started Oct 2024; status: completed.
02
Drugs
dobutamine
03
Conditions
septic shocksepsisseptic cardiomyopathy (SCM)
Beyond the preview
Go deeper on 2024-517839-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517839-50-00.